Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Focuses On Its Next Blockbuster: Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

Amgen is expected to announce a JV in Japan soon, the company said during a business strategy meeting last week. It expects China, Japan and other emerging markets to bring in roughly $1 billion more in revenue by 2015.

You may also be interested in...



Defender Or Opponent? Amgen Straddles The Biosimilar Line

Amgen revealed plans to develop and launch biosimilar versions of Abbott’s Humira and Johnson & Johnson’s Remicade – two competitors to its blockbuster anti-TNF Enbrel – during an investor meeting in New York City Feb. 7.

After Brazil Onto China? Amgen Unveils Emerging Market Strategy

The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say

Takeda Makes $1 Billion Move For Amgen Development Rights

Eyeing the looming 2011 patent expiration of its top-seller Actos (pioglitazone), Takeda has acquired exclusive Japanese development and commercialization rights, and in one case global rights, to 13 of Amgen's clinical candidates, at a potential cost of up to $1.2 billion

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel